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Abstract
BACKGROUND & AIMS—The role of tobacco smoke in the etiology of inflammatory bowel 
disease (IBD) is unclear. We investigated interactions between genes and smoking (gene–smoking 
interactions) that affect risk for Crohn’s disease (CD) and ulcerative colitis (UC) in a case-only 
study of patients and in mouse models of IBD.
METHODS—We used 55 immunochip-wide data sets that included 19,735 IBD cases (10,856 
CD cases and 8879 UC cases) of known smoking status. We performed 3 meta-analyses each for 
CD, UC, and IBD (CD and UC combined), comparing data for never vs ever smokers, never vs 
current smokers, and never vs former smokers. We studied the effects of exposure to cigarette 
smoke in Il10−/− and Nod2−/− mice, as well as in Balb/c mice without disruption of these genes 
(wild-type mice). Mice were exposed to the smoke of 5 cigarettes per day, 5 days a week, for 8 
weeks, in a ventilated smoking chamber, or ambient air (controls). Intestines were collected and 
analyzed histologically and by reverse transcription PCR.
RESULTS—We identified 64 single nucleotide polymorphisms (SNPs) for which the association 
between the SNP and IBD were modified by smoking behavior (meta-analysis Wald test 
P<5.0×10−5; heterogeneity Cochrane Q test P>.05). Twenty of these variants were located within 
the HLA region at 6p21. Analysis of classical HLA alleles (imputed from SNP genotypes) 
revealed an interaction with smoking. We replicated the interaction of a variant in NOD2 with 
current smoking in relation to the risk for CD (frameshift variant fs1007insC; rs5743293). We 
identified 2 variants in the same genomic region (rs2270368 and rs17221417) that interact with 
smoking in relation to CD risk. Approximately 45% of the SNPs that interact with smoking were 
in close vicinity (≤1 Mb) to SNPs previously associated with IBD; many were located near or 
within genes that regulate mucosal barrier function and immune tolerance. Smoking modified the 
disease risk of some variants in opposite directions for CD vs UC. Exposure of IL10-deficient 
mice to cigarette smoke accelerated development of colitis and increased expression of interferon 
gamma in the small intestine, compared to wild-type mice exposed to smoke. NOD2-deficient 
mice exposed to cigarette smoke developed ileitis, characterized by increased expression of 
interferon gamma, compared to wildtype mice exposed to smoke.
CONCLUSION—In an analysis of 55 immunochip-wide data sets, we identified 64 SNPs whose 
association with risk for IBD is modified by tobacco smoking. Gene–smoking interactions were 
confirmed in mice with disruption of Il10 and Nod2—variants of these genes have been associated 
with risk for IBD. Our findings from mice and humans revealed that the effects of smoking on risk 
for IBD depend on genetic variants.
Keywords
animal model; nicotine; inflammation; gene–environment interaction
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Inflammatory bowel diseases (IBD), including Crohn’s disease (CD; MIM 266600) and 
ulcerative colitis (UC; MIM 191390), are chronic lifelong illnesses of early onset that 
seriously impede the quality of life of patients and their families. IBD is affecting more than 
2.5 million people in Europe (~0.5%) and is becoming increasingly frequent in Asia and in 
developing countries.1 The etiology of IBD involves both genetic and environmental factors, 
but the biological mechanisms of IBD development are still poorly understood. In particular, 
little is known about the possible role of gene–environment interaction (G×E) in IBD. In 
consequence, despite the many genotype-phenotype associations that have been identified in 
past genome-wide association studies (GWAS), more than 70% of the heritability of IBD is 
still unaccounted for.1–3
Smoking is the only well-established environmental risk factor for IBD.4–6 Early case-
control studies revealed an increased risk for both CD and UC in former smokers whereas 
current smoking seems to predispose to CD, but to protect against UC.6,7 This differential 
effect on risk was recently confirmed in a large prospective study of 229,111 women from 
the US Nurses’ Health Study6 where the CD hazard ratio was found to be 1.35 for former 
and 1.90 for current smokers, using never smokers as a reference. By contrast, the UC 
hazard ratio was equal to 1.56 for former, but 0.86 for current smokers. However, with a 
95% confidence interval ranging from 0.61 to 1.20, the apparent UC protective effect of 
current smoking was not statistically significant.
The etiological role of smoking in IBD is not yet fully understood mainly because of the 
complex chemical composition of tobacco smoke.8 Many candidate mechanisms appear 
worth consideration, including epigenetic changes that alter gene expression relevant to the 
innate and adaptive immune responses.8 Smoking also induces compositional changes of the 
gut microbiota, which provides a plausible link to disease etiology as well.9,10 Other 
possible mechanisms involve the post-translational modification of key proteins by 
constituents of tobacco smoke that activates the immune response and induces inflammation. 
For example, smoking has been found to induce citrullination of various proteins.11 
Citrullination affects the 3-dimensional structure of proteins in such a way that the latter 
may unfold and interior domains become exposed that can subsequently act as antigens. In 
rheumatoid arthritis, for example, smoking has been identified as an environmental trigger of 
anti-citrulline immunity in individuals with particular HLA-DRB1 ‘shared epitope’ alleles, a 
mechanism that might also explain why UC risk stays high even decades after smoking 
cessation.6,12
G×E studies are one way to unravel the biological mechanisms of disease development. As 
yet, however, only few studies of interactions between genes and smoking (gene–smoking 
interactions) have been conducted in the context of IBD.13–15 One of these studies reported a 
statistically significant interaction between NOD2 gene variant 1007fs, predisposing to CD, 
and both ever and current smoking.13 Two other small studies observed a significantly 
higher risk of CD for smokers among GG homozygotes for SNP rs2241880 in the ATG16L1 
gene and among CC (wild-type) homozygotes for SNP rs1343151 in the IL23R gene.14,15
So far, gene–smoking interactions in IBD have not been investigated at a genome-wide level. 
Using the genotype data available from the International Inflammatory Bowel Disease 
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Genetics Consortium (IIBDGC), we therefore investigated whether the relative IBD risk of 
smokers is modified by any of the genetic variants included on the Illumina Immunochip 
itself, or by variants in the HLA region that can be imputed from Immunochip data using 
publicly available databases. For that purpose, we adopted a two-tiered approach, including 
the verification in control individuals of the gene–smoking independence assumption 
implicit to the case-only design (stage I), followed by a case-only analysis to identify gene–
smoking interactions (stage II). The epidemiological findings were complemented by 
functional studies of mice deficient for two of the genes identified as potential G×E partners 
and which encode for interleukin-10 (referred as Il10) and nucleotide-binding 
oligomerization domain 2 protein (referred as Nod2).
Materials and Methods
IBD Immunochip Dataset
All DNA samples used in the present study were collected through the IIBDGC and 
originated from 48 sites in 17 countries in Europe, North America and Australia.2 
Genotyping with the Immunochip custom genotyping array (Illumina) was performed in 34 
batches in 11 different centers, as described elsewhere.2 After quality control,16 genotype 
data for a total of 132,890 SNPs with minor allele frequency >1% were tested for an 
interaction with smoking. For SNPs identified as potential G×E partners, additional quality 
control was carried out by visual inspection of the corresponding cluster plots.
Only samples with known smoking status were included in our study. We confined our meta-
analyses to those IIBDGC centers that provided at least 10 samples with either CD or UC in 
each of the three smoking categories (never, current or former), which yielded a total of 
19,735 cases (10,856 CD, 8879 UC; Table 1). Ten of the participating centers also had 
genotype data from controls available (n=8143), 60% of which (n=4887) were of known 
smoking status.
To study the specific role of the HLA region, we used imputed classical HLA alleles for the 
19,735 cases of interest from a previous IIBDGC study16 (see Supplementary Methods).
Animal Studies
All animal studies were approved by the local investigational review board (AF 16/20090) in 
an accredited establishment at the Institute Pasteur de Lille (N° B59-108) according to 
governmental guidelines N°86/609/CEE. Age- and gender-matched Nod2-deficient 
(Nod2−/−), Interleukin 10-deficient (Il10−/−) and control Balb/c mice (without disruption of 
these genes; wild-type mice) had free access to a standard laboratory chow diet in a half-day 
light cycle exposure and temperature-controlled environment. 3R4F research cigarettes were 
purchased from the University of Kentucky. Eight to ten week-old mice were exposed to the 
smoke of 5 cigarettes per day, 5 days a week, for 8 weeks, in a ventilated smoking chamber 
(InExpose® System, Emka, Scireq, Canada). The control group was exposed to ambient air.
Formalin-fixed, paraffin-embedded colon specimens were blindly scored for inflammation 
by two investigators (see Supplementary Methods). Relative mRNA levels were determined 
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in colon samples according to standard methods using Actb as an internal reference gene 
(see Supplementary Methods).
Statistical Analysis
All statistical analyses of the human data were performed with either PLINK17 or the R 
software (v. 3.2.1), as appropriate. The statistical significance of pairwise SNP-smoking 
interactions was assessed by logistic regression analysis as implemented in PLINK,17 
following a case-only approach.18 We employed an additive allelic model of the genotype-
phenotype relationship and encoded individual SNP genotypes (G) by allele counts. 
Genotypes were treated as predictor variables whereas the binary smoking status (E, see 
below) was treated as the response variable, i.e.
(1)
Following Piegorsch et al,18 we do not include any additional predictor variables, such as 
age or sex, into the model.
Any significant association between G and E that occurs in cases points towards G×E at the 
population level, provided that the two assumptions underlying the case-only design are met, 
namely that (i) the disease is sufficiently rare (i.e. prevalence <5%) and (ii) G and E are 
uncorrelated in the general population.18 Note that the case-only approach does not involve 
any further assumptions. The case-only paradigm is exemplified in Supplementary Table 10 
for SNPs rs17221417 and rs2270368 from the NOD2 gene region. Conceptually, 
multiplicative interaction between G and E is defined as the extent to which the true joint 
effect of G and E differs from the product of the two individual effects. From a case-only 
study, the genotypic odds ratio (OR) for exposure, i.e. the odds of E given the presence of G 
divided by the odds of E given the absence of G, can be derived by taking the antilog of the 
θ estimate (equation 1). One premise of the case-only design is that this OR can be 
interpreted as the multiplicative interaction between G and E on disease risk.
We performed a two-tiered G×E study separately for CD, UC and IBD (i.e. CD and UC 
combined). In stage I, the validity of the G-E independence assumption underlying the case-
only design was assessed for all 132,890 SNPs. To this end, the logistic regression model of 
equation 1 was fitted to the available control data. In total, 15,196 SNPs were removed 
because of a nominally significant violation of the G-E independence assumption in controls 
(meta-analysis p<0.05) for at least one of the three smoking contrasts never vs ever, never vs 
current or never vs former, leaving 117,694 SNPs for stage II.
In stage II, case-only analyses of gene–smoking interaction were carried out for all 117,694 
SNPs and for 11,248 variants in the HLA region separately for each participating center. 
Population stratification correction was performed in individual study centers, following a 
recently proposed genomic control-based approach for case-only studies19 (see 
Supplementary Methods).
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The case-only analyses were carried out in triplicate, each time considering one of the three 
smoking contrasts never vs ever, never vs current and never vs former (Table 1). For meta-
analysis, fixed- and random-effect models were fitted to the results using PLINK. A SNP 
was considered worth further consideration if the meta-analysis gene–smoking interaction 
(Wald) test yielded p<5.0×10−5 and the heterogeneity (Cochrane Q) test yielded p>0.05. 
Note that these criteria were not meant to control the family-wise error rate, i.e. define a 
threshold for genome-wide statistical significance. In recognition of many previous human 
studies, and particularly our own mouse data (see below), the present study was not geared 
towards disproving a genome-wide lack of gene–smoking interaction for IBD (e.g. the 
‘global null hypothesis’) but rather served to identify the strongest candidate genes for G×E. 
Thus, the significance thresholds employed here served as sensible filters to prioritize 
nominally significant findings. We also calculated the false discovery rate20 (FDR) for each 
SNP to control the estimated proportion of false positive results among the identified 
potential G×E. We adopted 0.1 as a common threshold for the FDR in subsequent 
considerations. At the chosen significance level of α=5.0×10−5, the meta-analysis of the 
never vs ever IBD cohorts (n=19,735) had approximately 90% power21 to detect even a 
small G×E effect (OR=1.15), assuming a risk allele frequency of 0.15, a smoking frequency 
of 0.4, a genetic OR of 1.2 (as observed, on average, for IBD1) and a smoking OR of 1.4.6 
Expectedly,21–23 a case-control analysis including all cases plus the available 4887 controls 
with known smoking status would have yielded dramatically smaller power of only 3%, 
assuming the same interaction effect and leaving all other parameters unchanged. Since 
smoking rates differed between centers, we also investigated, for each of the 64 SNPs 
identified as potential G×E partners, the relationship between the center-specific interaction 
ORs and smoking rates, using Spearman correlation coefficient.
To assess whether a given region harbored multiple independent gene–smoking interactions, 
regions with more than one SNP with p<5.0×10−5 were scrutinized further. All analyses 
were repeated including into the respective statistical model the SNP with the smallest gene–
smoking interaction p value within a given 1 Mb region (henceforth called the ‘top SNP’) as 
a mandatory predictor. SNPs with a nominally significant Wald test (p<0.05) in the 
conditional analysis were deemed independent gene–smoking interaction partners.
To assess whether the gene–smoking interactions identified in our study overlapped or 
coincided with previously reported IBD associations,1,24 pair-wise linkage disequilibrium 
was estimated in the available control samples (n=8143) irrespective of whether smoking 
information was also available or not. To this end, r2 was computed in each center between 
pairs of SNPs no more than 1 Mb apart, where one showed an interaction in our study and 
one had been identified as a genetic main effect in a previous GWAS,1,24 followed by the 
calculation of a sample size-weighted average of the center-wise r2 values.
In order to identify SNPs that show interaction with smoking in opposite direction in CD 
and UD, we searched for SNPs with a meta-analysis gene–smoking interaction (Wald test) 
p<0.01 and a heterogeneity (Cochrane Q test) p>0.05 for which the case-only G×E OR for 
one and the same risk allele was reversed between CD and UC (i.e. OR<1 in CD and OR>1 
in UC, or vice versa).
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We illustrated the validity of the case-only approach by performing case-control analyses of 
CD for two selected SNPs from the NOD2 gene region (see Supplementary Methods). These 
calculations naturally had to be confined to the centers that provided controls with smoking 
information. We also carried out stratified analyses of the genetic main effects of the two 
SNPs in never smokers and current smokers. We confined the genome-wide analysis to a 
case-only approach because this has much higher power than a case-control approach, as 
was noted above.
The mice data were analyzed statistically using a Kruskal-Wallis test or two-way ANOVA as 
implemented in GraphPad Prism 5 Version 5.02. Statistical significance was defined as 
p<0.05; measurements were summarized as mean ± standard error of the mean.
Functional annotation of the interacting SNPs and gene prioritization, pathway and tissue/
cell type enrichment analysis, and regional linkage disequilibrium plots and annotation of 
association boundaries were performed as described in the supplementary methods section 
using publicly accessible databases.
Results
SNP-Smoking Interaction
Three Immunochip-wide meta-analyses of the interaction between smoking behavior 
(contrasts never vs ever, never vs current and never vs former) and genotype (117,694 SNPs 
complying with the G-E independence assumption in controls, minor allele frequency >1%) 
were performed separately for CD, UC and IBD (i.e. CD and UC combined). Manhattan 
plots of the meta-analyses results highlighted several potentially interacting loci (Figure 1 
and Supplementary Figure 1). Study-wide λ values, calculated to adjust for potential 
population stratification, were found to be small to moderate, with a maximum of 1.15 
obtained in the “USA, Los Angeles” CD cohort (Supplementary Table 1 and Supplementary 
Figure 2).
With the never vs ever contrast, 46 interacting SNPs for CD (in 5 genomic regions), 53 
interacting SNPs for UC (in 1 genomic region) and 65 interacting SNPs for IBD (in 3 
genomic regions) initially fulfilled our filter criteria (Supplementary Table 2). When 
conditioning upon the genotypes of the region-specific top SNPs, 1 (CD), 1 (UC) and 3 
(IBD) additional SNPs were found to exhibit residual SNP-smoking interaction of nominal 
significance (Supplementary Table 3), thereby indicating potentially independent interaction 
signals from the same genomic regions. Overall, a total of 6 SNPs (5 top, 1 additional 
independent), 2 SNPs (1, 1) and 6 SNPs (3, 3) were thus identified as interacting with 
smoking for CD, UC and IBD risk, respectively, in the never vs ever smoker meta-analyses. 
Similarly, meta-analyses with the never vs current and never vs former smoker contrasts 
identified an additional 18 interacting SNPs (13 top, 5 additional independent) for CD, 24 
SNPs (21, 3) for UC and 23 SNPs (18, 5) for IBD (Supplementary Tables 4–7). In summary, 
considering at least one of the three smoking contrasts and after adjustment for possible 
population stratification, 19 SNPs for CD, 25 SNPs for UC and 25 SNPs for IBD were 
identified as interacting with smoking according to our filter criteria (Wald test p<5.0×10−5, 
Cochrane Q test p>0.05). Since two SNPs (rs9268923, rs117782746) were overlapping 
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between CD and IBD and three SNPs (rs3129890, rs7747521, rs116883185) were 
overlapping between UC and IBD, the total number of unique SNPs was 64 (Figure 2, Table 
2; for regional linkage disequilibrium plots, see Supplementary Figures 3–11). Some 52 of 
these 64 SNPs yielded a false discovery rate (FDR) below 0.1. Interestingly, the largest 
number of interacting markers was identified with the never vs current smoker contrast for 
UC (middle panel in Figure 2), but with the never vs former smoker contrast for CD (bottom 
panel). No correlation became apparent for any SNP between the center-specific smoking 
rates and the center-specific interaction ORs (Supplementary Figure 12). For the NOD2 risk 
locus, we replicated the interaction between tobacco smoke exposure and the frameshift 
polymorphism fs1007insC (rs5743293; p=4.5×10−3 for never vs current smoker contrast in 
CD) and identified two suggestive independent SNP-smoking interactions in the same gene 
region (rs2270368, p=2.9×10−5, never vs current; rs17221417, p=3.3×10−6; never vs 
current) by means of conditional analysis (Supplementary Table 8).
In addition to the candidate variants in Table 2, seven nominally significant interactions 
(Wald test p<0.01) were found to be of opposite direction for CD and UC (Table 3) which 
implies that one and the same allele of each of these SNPs increases the risk of CD in 
smokers, but at the same time protects smokers against UC.
By the time of our study, a total of 238 IBD-associated SNPs had been identified in 
GWAS.1,24 To assess their possible overlap with gene–smoking interactions, we quantified 
the level of linkage disequilibrium between the 64 unique SNPs identified in our gene–
smoking interaction study with those 229 IBD-associated SNPs for which we had genotype 
data available. Some 29 interacting SNPs were found to be located within 1 Mb of a GWAS-
identified SNP. However, only four pairs of SNPs (IBD-associated, smoking interacting) 
were found to be in moderate linkage disequilibrium (e.g. r2>0.05; Supplementary Table 9).
To further illustrate the validity of the case-only approach, we performed smoking-stratified 
case-control analyses, considering never vs current smoker contrast, for two selected SNPs 
from the NOD2 gene region (Supplementary Table 10). In the case of rs2270368, no 
association with CD was evident in current smokers (OR= 0.96, 95%CI= [0.78, 1.16]), but a 
protective effect of the minor allele emerged in never smokers (OR= 0.77, 95%CI= [0.69, 
0.85]). Similarly, a smaller CD risk was found to be associated with rs17221417 in current 
smokers (OR= 1.28, 95%CI= [1.07, 1.52]) than in never smokers (OR= 1.74, 95%CI= [1.58, 
1.91]).
HLA-Smoking Interaction
In our focused analyses of classical HLA-alleles, a gene–smoking interaction meeting our 
filtering criteria was observed for 4 alleles in CD, 1 allele in UC and 5 alleles in IBD (Table 
4). Overall, unique alleles were identified with suggestive evidence of gene–smoking 
interaction with at least one smoking-status contrast. All of these alleles were found to 
comply with the G-E independence assumption in controls.
Functional Annotation of Interacting Variants
We functionally annotated the 64 SNPs identified as potentially interacting with smoking for 
at least one of three smoking contrasts (see Supplementary Methods). For 37 of the 
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interaction signals (58%), the lead SNP mapped within the transcript of a known gene while 
27 signals were located in intergenic regions (Supplementary Table 11). The interacting 
SNPs included one coding missense variant (rs41275313) in the SLU7 gene. However, all 
coding SNPs were predicted to be benign (Supplementary Table 12). Non-coding SNPs 
rs76903200 (ZNF804A; intronic), rs79716898 (intergenic between IRGM and ZNF300) and 
rs62407243 (intergenic between HLA-E and GNL1) were found to be potentially deleterious 
based upon the prediction of reduced organismal fitness (CADD scores; Supplementary 
Table 12). Among coding SNPs that were in strong linkage disequilibrium (r2>0.8 in the 
1000 Genomes European samples; n=376 variants) with the 64 lead SNPs (see Methods), 
we identified another 5 synonymous SNPs at the ZNF300, IRGM, UHRF1BP1 and NOD2 
(2x) gene loci and 1 non-synonymous SNP at the GRAMD2 gene (Supplementary Table 13).
We also examined which of the 64 lead SNPs and of the SNPs in strong linkage 
disequilibrium (r2>0.8) with the lead SNPs mapped to eQTLs from GTEx and Geuvadis 
eQTL studies,25 or to functional annotations of the noncoding genome in different cell types 
provided by the Roadmap Epigenomics26 and ENCODE27 projects, using web tool 
HaploReg28 (Supplementary Table 14; see Methods). The results are summarized in 
Supplementary Figure 13.
Pathway and Cell Type Enrichment Analyses
To ascertain whether genes at the putatively interacting loci were highly expressed in certain 
tissue/cell types, we conducted pathway and tissue/cell type enrichment analyses using 
DEPICT29 with 77,840 microarray gene expression profiles from human, rat and mouse and 
209 tissue/cell type annotations30 (see Supplementary Methods). From DEPICT, we 
identified 24 gene sets (Supplementary Table 15) and 20 tissues (Supplementary Table 16) 
with significant enrichment of genes within the suggested interacting loci (false discovery 
rate <0.01). The results mainly point towards perturbation of immune response pathways in 
blood.
Loss of Nod2 and Il10 renders mice susceptible to intestinal inflammation in response to 
cigarette smoke exposure
The possible impact of cigarette smoke on intestinal homeostasis was next evaluated in mice 
that were deficient for either Il10 or Nod2, two proteins encoded by genes that were 
identified as potential smoking-interacting genes in our human data (Table 2). While no 
signs of disease were apparent in wild-type (WT) mice after 8 weeks of cigarette smoke 
exposure, smoking Il10−/− mice experienced greater body-weight loss (Figure 3A), increased 
disease activity index (Figure 3B, significant gene-smoking interaction, p=0.01 at day 62), 
and an accelerated development of rectal prolapses (Figure 3C). Consequently, cigarette 
smoking markedly reduced the colon length of Il10−/− mice, compared to similarly treated 
WT animals (Figure 3D). While histological analysis failed to reveal any signs of 
inflammation in WT mice, a greater infiltration of immune cells within the colonic mucosa 
(Figures 3E and 3F) and an enhanced expression of Ifng transcipts in the ileum were 
observed in smoking Il10−/− mice (Figure 3G). Likewise, Nod2−/− mice also showed higher 
expression of Ifng in their ileum, but lacked signs of colitis and prolapse development 
(Figure 3G and Supplementary Figure 14). Taken together, our data suggest a strong 
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protective role of both Il10 and Nod2 on intestinal homeostasis in response to tobacco 
smoking.
Discussion
We performed an extensive meta-analysis to investigate possible gene–smoking interactions 
in relation to the risk for CD, UC or IBD. To this end, we used the existing Immunochip-
wide data collated by the IIBDGC. Our analysis identified 19 SNPs for CD, 25 SNPs for UC 
and 25 SNPs for IBD that potentially interact with regard to disease risk considering at least 
one of three smoking contrasts (never vs ever, never vs current, or never vs former). 
Interestingly, the largest number of interacting SNPs was identified with the never vs current 
contrast for UC, but with the never vs former contrast for CD.
Our findings are highly relevant to furthering the understanding of IBD etiology for various 
reasons. First, the discrepancies observed between the three smoking contrasts suggest that 
the precise mechanism by which the smoking-induced disease risk of an individual is 
modified by their genetic make-up differs between past and current smokers. This disparity 
has not been considered in previous epidemiologic studies.7,31–34 Second, we were able to 
show, for the first time, that some of the modification of smoking-induced IBD risk is 
brought about by more than one genetic factor located in the HLA region. Third, a clear-cut 
dependence upon smoking behavior became apparent in the HLA region for CD risk, but not 
UC risk. Such a differential role of G×E in the two IBD sub-entities may be a key to 
understanding why the smoking-induced risk for UC may still increase with time even 
decades after smoking cessation.6 Finally, the scope and nature of gene–smoking interaction 
in IBD may be exemplary for other diseases. For example, in line with our own results, 
BTNL2 and HLA-DRB5 were recently identified as candidate interaction signals as well in 
a rheumatoid arthritis SNP-smoking interaction study.35 Some 29 of the 64 unique 
interacting SNPs (45%) were found to lie in close vicinity (≤1Mb) of genes that were 
previously identified as being disease-associated in GWAS, including IL10 (Table 2).1,24 
However, in view of the general lack of strong linkage disequilibrium between interacting 
and IBD-associated SNPs, we conclude that the respective association and interaction 
signals may highlight different genetic effects. Thus, even if two functionally relevant 
variants lie in the same gene or functional unit, the ensuing disease risk may still be 
modified by smoking for one variant, but not for the other. Along the same line, our focused 
analysis of the HLA region revealed that only a subset of the IBD-predisposing alleles16 was 
found to interact with smoking as well. We also identified seven SNPs that seemed to 
interact with smoking in opposite directions with regard to CD and UC. Since statistical 
interaction can be viewed from different angles, this difference may mean one of two things: 
Either a genetic mechanism predisposing to one of the two sub-entities is rendered protective 
against the other in the presence of smoking, or the effect of smoking in relation to one sub-
entity is reversed in comparison to the other by that mechanism. Simply put, a certain 
genotype may simultaneously render smoking a risk factor for CD and a protective factor 
against UC.
We used web-based computational tools for evaluating the potential functional consequences 
of the interacting SNPs. Only few of the SNPs were found to have a known effect rendering 
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a firm biological interpretation of the results difficult (Supplementary Tables 12–16). 
However, many of the interacting SNPs are located near or within genes that may be 
involved in, or interfere with, mucosal barrier function (e.g. NOD2, IRGM, CDH1 and 
GPSM336) or the adaptive immune response (e.g. IL2RA, CCL11, CCL8, MICB, IL10 and 
the HLA region). Several SNPs in the HLA region were also found to interact with smoking 
in relation to either CD, UC or IBD (Table 2), including one SNP (rs3129890) that had 
previously been found to be associated with a high risk of rheumatoid arthritis among 
smokers.35 Moreover, we identified six HLA alleles with suggestive gene–smoking 
interaction (namely HLA-DRB3*91:01, HLA-B*57, HLA-B*57:01, HLA-DQA1*02:01, 
HLA-DQB1*02:02 and HLA-DRB1*07:01). Of these six alleles, four were identified 
previously to have a main effect16 either on CD risk (HLA-B*57:01, HLA-DQA1*02:01 and 
HLA-DRB1*07:01) or on UC risk (HLA-DRB1*07:01, HLA-DQA1*02:01 and HLA-
DQB1*02:02). The overlap between genetic interaction and main effect signals suggests that 
perturbation of the adaptive immune response may be one important mechanism by which 
smoking differentially confers risk to either CD or UC. Also of interest in this regard are the 
seven SNPs that interact with smoking in opposite directions in CD and UC (Table 3), which 
included one SNP (rs176095) that has been found to be associated with atopic dermatitis37 
and asthma38 before. This SNP is located on chromosome 6 near the GPSM3 gene that 
regulates monocytes function and inhibits NLRP3-coupled inflammasome activation.36 
NLRP3 is a member of the NOD-like receptor (NLR) family of intracellular sensors of 
danger signals, such as pathogen-associated molecular patterns (PAMPs), that controls 
IL-1α response to cigarette smoke exposure in mice.39
Our epidemiological results were exemplarily corroborated by the observation that Nod2- 
and Il10-deficient mice that were experimentally exposed to cigarette smoke had a greater 
risk of ileitis than similarly treated WT mice. One possible explanation for this difference 
could be that cigarette smoke exposure compromises the barrier function of the small 
intestine more effectively as a result of lower NOD2 gene expression and a consequent 
reduction of chemokine and antimicrobial peptides secretion.40 Likewise, long term 
exposure to cigarette smoke decreases the number of Foxp3+ cells and the expression of 
IL-10 which, in combination, represses IFN-γ production.41 Equally important is that a 
greater risk of colitis was observed in Il10-deficient mice that were exposed to cigarette 
smoke but not in wild-type and Nod2-deficient mice, suggesting a differential role of Il10 on 
disease location in response to cigarette smoke.
We employed the powerful albeit rarely used case-only design that relies upon two key 
assumptions, namely that (i) the disease is sufficiently rare (i.e. prevalence <5%) in the 
general population and that (ii) G and E are uncorrelated in the general population. Case-
only studies offer a number of methodological advantages compared to traditional case-
control studies, including higher per-sample power and better exposure data quality.18,42,43 
The samples available to us provided 90% power for a small interaction effect (OR=1.15) in 
a case-only analysis, but only 3% power in a case-control analysis. However, since the 
validity of the results of case-only analyses depends upon the validity of the G-E 
independence assumption, the latter must be assessed empirically, for example, in control 
data from GWAS. This requirement cannot be obviated because many genetic variants are 
known to be associated with smoking behavior at the population level.44 Indeed, in our 
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study, 15,196 SNPs violated the G-E independence assumption with at least one of the three 
smoking contrasts considered (never vs ever, never vs current, or never vs former). Only one 
of these, a synonymous SNP (rs1051730) in the nicotinic receptor gene CHRNA3 at 15q25, 
has been identified so far to be associated with smoking behavior.45 For all other G-E 
associations notified in the controls of our study, the underlying reason remains unclear 
because none of the respective SNPs coincides with any previously identified association 
with smoking behavior.44,45
One limitation of our study is that the smoking data were abstracted locally from existing 
clinical and/or research records which may have introduced some variability across centers 
in the way the data were initially recorded. To mitigate this, we focused on a clear-defined 
classification of smoking behavior as either (i) current (smoking within the past 3 months), 
(ii) ever (current or ex-smoker) or (iii) never as of the date of diagnosis (cases) or 
recruitment (controls). We also ascertained the year in which the subjects first started and 
finally stopped smoking, as applicable, and used this information in conjunction with the 
year of diagnosis to verify that each center was applying the smoking definition correctly. 
Since our study employed meta-analysis techniques to evaluate gene–smoking interactions 
at the center level, any remaining measurement error would have resulted only in a loss of 
power but not in an increased type 1 error rate. Moreover, the center-specific interaction 
estimates were not found to be related to the center-specific smoking rates for any of the 
interacting SNPs, an observation that reinforces our notion that differential assessment of 
smoking behavior was unlikely to affect the validity of our results. This notwithstanding, 
without accurate information on the actual number of cigarettes smoked (which would have 
been much more difficult to obtain), we were unable to account for potential dose-dependent 
effects of smoking.
In summary, our genome-wide study of G×E in IBD identified 64 SNPs with strong 
evidence for a complex modifying role in the smoking-related etiology of IBD. Functional 
studies in mice lend additional experimental support to these epidemiological findings by 
highlighting a direct effect of Il10 and Nod2 on disease risk in response to smoking. Our 
study thus sheds new light on the role of smoking as an important component of IBD 
pathogenesis interacting with the genetic background of at-risk individuals.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Manhattan plots of six Immunochip-wide meta-analyses highlighting potentially 
smoking-interacting loci for CD and UC
Panels 1–3 (from top) refer to three different smoking contrasts for CD: never vs ever, never 
vs current and never vs former. Similarly, panels 4–6 (from top) refer to three different 
smoking contrasts for UC. The horizontal dashed line indicates the threshold (p=5.0×10−5) 
for suggestive evidence of gene–smoking interaction. All SNPs included in the analyses 
complied with the G-E independence assumption underlying the case-only design, leaving 
117,694 SNPs for case-only meta-analysis. Top SNPs from Table 2 and the gene context 
(see Table 2 legend for gene context definition) are shown above the suggestive threshold 
line (in bold). Manhattan plots for IBD (i.e. CD and UC combined) are provided as 
Supplementary Figure 1.
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Figure 2. Visualization of SNPs identified as interacting with smoking (
Table 2).
The odds ratio is shown for all markers with suggestive gene–smoking interaction 
(p<5.0×10−5); gene context (see Table 2 legend for gene context definition) is provided with 
each rs-number and chromosome numbers are given in parentheses. The three panels refer to 
different smoking contrasts, namely never vs ever (top), never vs current (middle) and never 
vs former (bottom). The square color refers to the IBD type (CD: red, UC: blue, IBD: 
black), large squares mark meta-analysis (Wald test) p values <5.0×10−5.
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Figure 3. Impact of interleukin-10 and Nod2 deficiency on the risk of intestinal inflammation in 
cigarette smoke-exposed mice
Wild-type (WT) and Il10−/− mice were exposed to cigarette smoke (CS), 5 days a week, over 
a period of 8 weeks. (A) Changes in body weight. (B) Disease Activity Index. (C) Prolapsus 
apparition under CS exposure in Il10−/− mice. (D) Colon length. (E) Representative H&E 
stainings. (F) Histological score. (G) Relative expression level of Ifng gene in the ileal tissue 
of WT, Nod2-deficient and Il10-deficent mice that were either exposed to CS or not. 
*p<0.05, ***p<0.001 (Kruskal-Wallis test). Data are representative of two independent 
experiments.
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